♪Please type a plus sign (+) inside this box → +	≜ ?lease typ	a plus sign	(+) inside	this box	→	+
--	---------------------	-------------	------------	----------	----------	---

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known						
Application Number	10/075,954					
Filing Date	February 13, 2002					
First Named Inventor	Charles Andrianjara, et al					
Group Art Unit	1614-1624					
Examiner Name	Not Yet Assigned					
Attorney Docket Number	A0000476-CFP					

				U.S. PATENT DOCU	MENTS	Class /Subclass
Exeminer Initials	Cite No.1	U.S. Patent Document Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pases (Columns, Lines, / Winde Ricklycht/ Pasaudes of Peleyant Faluras Aspalar
TOUT		5,948,780		Peterson, Jr., et al	09/07/1999	514/255
TW		6,008.243		Bender, et al	12/28/0199	514/422
						\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
						7 14 11
						CC/C 3
				*		1600/2900
 i						17 160010
						300
				-		

	FOREIGN PATENT DOCUMENTS											
Examiner	Cite	L	Foreign Patent Docum		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant					
Initials*	No.1			Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶					
TNI		wo	01/63244 A1		Chen, et al	08/30/2001						
								+				
		╂╼┼╸						+				
								-				
<u> </u>	-					<u> </u>		+				
]										

Examiner	120	Date	1/2rd	1 . 1
Signature	Mon	Considered	6/3	104

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	C
П	
\subseteq	
П	ļ
<	•
Ш	

!	Please type a plus sign (+) inside this box	→	+

Please type a plus sign (+) inside this box + + Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

bstitute for form	1449B/PTO	•

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complet if Known						
Application Number	10/075,954					
Filing Date	February 13, 2002 🔘					
First Named Inventor	Charles Andrianjara, et a					
Group Art Unit	1614					
Examiner Name	Not Yet Assigned					
Attorney Docket Number	A0000476-CFP 8 5					

/		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	8	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	2
TNT		MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitor Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361.	's",	
TNT		CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25	n	
INT INT		CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654.	,	
		·		
	,	<u></u>		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Examiner

Signature

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

F E (C) AD (S)							Ì	Ĵ.				÷	•	She	eet _1_	of <u>2</u>
FORM PTO-	144	(CO	ММ	ER	CE	MENT PATE	NT	ΑN	D		TTY. DOCKET NO. 0000476-CFP	SERIA 10/075		IEQ.	
SUPPLEMI S	ENT TAT	AL II	۱FC	ORM	IAI	ron		CLC		RÉ		PPLICANT Charles Andrianjara, et al			SE SE	MAY
		se seve										LING DATE Sebruary 13, 2002	GROU -1614-	1624	Ħ	0 7
									U.	S. P	AТ	ENT DOCUMENTS				2003
EXAMINER INITIAL		D	000	CUM	IEN	IT I	NUME			DA		NAME	CLASS	SUBCLASS	SAPPRO	DATE PRIATE
	4	\perp			-	$\frac{1}{1}$	\blacksquare	-	+						,	
						1			1							
	-		_		+	+	$\dashv \mid$	\downarrow	+	-			<u> </u>			
	+					\perp	$\forall \exists$	\dagger	\dagger							
							\coprod									
							F	<u>'O'</u>	<u>RF</u>	EIGN	N P	ATENT DOCUMENT				
		I	DO	CUN	ΛEΙ	NT	NUMI	BER		DA	TE	COUNTRY	CLAS	SS SUBCLAS	SS TRANS	LATION
TNT	V	w	o	9	9	6	4 4	0	0	12.1	6.99	wo	****		125	X
TNT	1/	-	0	9	7	4	3 2 1 9	┿	-	1 - 7 -		wo DE			-	X
7//1		D	Е	2	4	4	1 9	3	9	7/19	/3	1/6				
				_	_			Ļ	1	-						ļ
		Ш		_1					<u> </u>	<u> </u>						1
TNT	11				IVE uin: p 4: GA her elin	ERT azol 83-4 W/ mica nsky	ON, Ninones 486 • A, H, al Abs	et a	pote 1, "S CH of C	Studies HEMC	on particular on	ing Author, Title, Date bride glycoprotein Ilb/Illa inhibitors: ten receptor antagonists", Bioorgani cositive inotropic agents V", Chem I and AN 2001:1423935 for Order no. A comistry, Russia, 2000 > AN 2001:2519212, 2001:2519208 and CHS1938395, respectively, "Che	e substitute c & Medic Pharm Bul 1240/0056 , and 2001	d quinazoline inal Chemistr 1, 1988; 36(6) 5923 "Screeni :2519206 for	diones and y Letters, I , pp 2253-2 ing Collecti Order nos.	258 ¿
/ 2001. Chemical Abstract CHEMCATS: AN 2001:2624610, 2001:2320591, 2002:928648, 2002:925092, 2002:92666 and 2002:927094 for Order nos. STOCKIN-22756, A1336/0060317, STOCKIS-85693, STOCKIS-77305, STOCKIS-81043, and STOCKIS-82046, respectively, "Ambinter: Exploratory Library", Ambinter, Paris, 2002 Chemical Abstract CHEMCATS: AN 2001:1621701, 2001:1621700, 2001:1433023, 2001:1433022, and 2001:1433020 for Order nos. Z-007159, Z-007158, C-055659, C-055658, and C-055656, respectively,								:926648, 5, , 2002 <i>s</i>								
			}	- ": - C	Scie Ther H)-	nica dio	fic Exe al Abs ne, 6-(han ract	ige i :: Al zylti	Produc ostract nio)-, R	t Lis No. UN 1	t", Scientific Exchange, Inc., USA, 54:2375e for Nesterov, et al., Comp 00382-60-3, USA 1960 s stract No. 128:243870 (1998:22455	2001 # ound: Pyr	imido '5,4-đ p	yrimidine-2	2, 4(1H,
		$\frac{}{}$	\ /	(s)	ynti her	nesi: nica	s of 6- al Abs	subs tract	c CA	PLUS	nazii : Ab	nes by using highly reactive lumazir stract No. 128:243871 (1998:22455	ne 6-triflate	e", Germany 1	997;17-22	
DO H		<u></u>	+	7 c	her	nica	l Abs	ract	CA	PLUS	: Ab	Germany 1997;41-44 stract No. 126:212115 (1997:10023 nethyllumazine with sulfur nucleoph				

Mom

6/3 10/04

O I P & CO 2003 12	•		St
FORM PTO	0-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A0000476-CFP	SERIAL NO. 10/075,954
	IENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Charles Andrianjara, et al	•
له	(Use several sheets if necessary)	FILING DATE February 13, 2002	GROUP 1614 1624

O	THER	DOCII	M	ENTS (Including Author, Title, Date, Pertinent Pages, etc)				
7	NT	√	П	Chemical Abstract CAPLUS: Abstract No. 107:58977 (1987:458977) for Sladowska, et al., "Synthesis and properties of amides of 1-benzyl-3-methyl-an 1-butyl-3-phenyl-7-methyl-4-oxo-2-thioxo (2,4-dioxo)-1,2,3,4-tetrahydropyrido '2,3-d!pyrimidine-6-carboxylic acids", Farmaco, Ed. Sci. 1986;41(12):954-963				
	1	/	¥	Chemical Abstract CAPLUS: Abstract No. 87:152121 (1977:552121) for Lespagnol, et al., "Study on antifolic agents. 1. Derivatives of 4-nitrobenzene-1,3-dicarboxylic acid", Bull. Soc. Pharm. Lille 1977;33(1):67-77				
	Chemical Abstract CAPLUS: Abstract No. 101:16805 (1984:416805) for Ghose, et al., "A general distance-geometry three-dimensional receptor model for diverse dihydrofolate reductase inhibitors", J. Med. Chem. 1984;27(7):901-914							
		V	ι	REITER, L. A., et al, "Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket", Bioorganic & Medicinal Chemistry Letters, 1999;9:127-132				
7,	VT	J	1	ĆHEN J. M., et al, "Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design", J. Am. Chem. Soc. 2000;122:9648-9654 (CITED ALSO IN FIRST IDS) r				
			+					
EX	AMINER		_ 	DATE CONSIDERED 6/3 rd/04				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

PTO/SB/17 (01-03) 6 2003 Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Complete if Known E TRANSMITTAL 10/075,954 Application Number Filing Date February 13, 2002 for FY 2003 ANDRIANJARA, ET AL First Named Inventor Effective 01/01/2003. Patent fees are subject to annual revision. Unknown **Examiner Name** Applicant claims small entity status. See 37 CFR 1.27 1614 **Art Unit** A0000476-CFP TOTAL AMOUNT OF PAYMENT (\$) 0.00Attomey Docket No. FEE CALCULATION (continued) METHOD OF PAYMENT (check all that apply) 3. ADDITIONAL FEES Money Other Check Credit card None arge Entity | Small Entity Deposit Account: Fee **Fee Description** Fee Paid Code (\$) Code Deposit 23-0455 Account 2051 65 Surcharge - late filing fee or oath 1051 130 Number Surcharge - late provisional filing fee or 50 2052 Deposit 1052 Warner-Lambert Company cover sheet Account Name 130 Non-English specification 1053 130 1053 The Commissioner is authorized to: (check all that apply) 1812 2,520 For filing a request for ex parte reexamination 1812 2,520 Credit any overpayments Charge fee(s) indicated below 920* Requesting publication of SIR prior to 1804 1804 920 ✓ Charge any additional fee(s) during the pendency of this application Examiner action Charge fee(s) indicated below, except for the filing fee Requesting publication of SIR after 1805 1.840 1805 1.840* **Examiner action** to the above-identified deposit account. Extension for reply within first month 1251 110 2251 **FEE CALCULATION** 205 Extension for reply within second month 2252 410 1252 1. BASIC FILING FEE 465 Extension for reply within third month 2253 1253 930 arge Entity Small Entity Fee Paid 725 Extension for reply within fourth month Fee Description 2254 1254 1.450 Fee Fee Code (\$) ode 985 Extension for reply within fifth month 1.970 2255 1255 Utility filing fee 1001 750 2001 375 2401 320 160 Notice of Appeal 1401 Design filing fee 2002 165 1002 330 160 Filing a brief in support of an appeal 320 2402 2003 Plant filing fee 1003 520 260 140 Request for oral hearing 1403 280 2403 Reissue filing fee 2004 375 1004 750 1,510 Petition to institute a public use proceeding 1451 1,510 1451 Provisional filing fee 1005 160 2005 80 55 Petition to revive - unavoidable 1452 110 2452 SUBTOTAL (1) (\$) 650 Petition to revive - unintentional 1,300 2453 1453 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1,300 650 Utility issue fee (or reissue) 2501 1501 Fee from Fee Paid 235 Design issue fee 2502 1502 470 Extra Claims below 10 **Total Claims** хЮ 630 2503 315 Plant issue fee 1503 Independent 130 Petitions to the Commissioner 130 1460 1460 Multiple Dependent 1807 50 1807 50 Processing fee under 37 CFR 1.17(q) 180 Submission of Information Disclosure Stmt Large Entity Small Entity 180 1806 1806 40 Recording each patent assignment per Fee Description Fee Fee FAA Code (\$) 8021 40 8021 Code (\$) property (times number of properties) Claims in excess of 20 1202 18 2202 375 Filing a submission after final rejection (37 CFR 1.129(a)) 2809 1809 750 Independent claims in excess of 3 1201 84 2201 42 375 For each additional invention to be Multiple dependent claim, if not paid 1810 750 2810 1203 280 2203 examined (37 CFR 1.129(b)) ** Reissue independent claims 1204 84 2204 42 375 Request for Continued Examination (RCE) over original patent 1801 750 2801 900 Request for expedited examination 900 1802 ** Reissue claims in excess of 20 1802 2205 9 1205 18 of a design application and over original patent Other fee (specify) **(\$)** 0.00 SUBTOTAL (2) *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0.00 or number previously paid, if greater; For Reissues, see above (Complete (if epplicable) SUBMITTED BY

SUBMITTED BY

Name (Print/Type)

Claude F. Purchase, Jr.

Registration No. (Attorney/Agent)

Signature

Complete (# epplicable)

Telephone 734 622-1692

Date 4/30/03

WARNING: Information on this form may become public. Credit card information should not be included on this form. Pr vide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

lease type a plus sign (+) inside this box --> +

129

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

a type a plus sign (+) inside this box + + Approved for use through 09/30/2000. OMB 0851-00784

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/075,954 February 13, 2002 **Filing Date** ANDRIANJARA, ET AL **First Named Inventor Group Art Unit** 1614 Unknown **Examiner Name** A0000476-CFP **Attorney Docket Number**

ENCLOSURES (check all that apply)								
✓ Fee Transm	nittal Form			ent Papers pplication)		After Allowance Communication to Group		
Fee	Attached		Drawing	(s)		Appeal Communication to Board of Appeals and Interferences		
Amendmer	nt / Response		Licensin	g-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
Afte	er Final			Routing Slip (PTO/SB/69) ompanying Petition		Proprietary Information		
Affic	davits/declaration(s)			to Convert to a nal Application		Status Letter		
Extension of	of Time Request		Power of Change Address	Attorney, Revocation of Correspondence	V	Additional Enclosure(s) (please identify below):		
Express Ab SUPPLE Information Certified C Document		Terminal Small Er	Disclaimer ntity Statement for Refund		Copy of all cited references A return postcard Authorization debit/credit charge account 23-0455			
	to Missing Parts/ Application			•				
Part	ponse to Missing Is under 37 CFR 2 or 1.53							
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm <i>or</i> Individual name	Claude F. Purchas	e, Jr.		•				
Signature	Rue	than	eif					
Date	3		7					

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:	s first class mail in an 4/30/03

Inja Cho Typed or printed name Signature

4/30/03 Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a p	lus sign (+)	inside this	box	->	+

Sheet

of

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
Trademark Office: U.S. DEPARTMENT OF COMMERCE

1				espond to a collection of information uni	less it contains a valid OMB control number plet if Known	-
Substitu	LEMENTAL	P10 	LOSURE	Application Number	10/075,954	
ENF	ORMATIO	N DISC	LOSURE	Filing Date	February 13, 2002	
STA	ATEMENT	RY AP	PLICANT	First Named Inventor	Charles Andrianjara	
<i>~</i>	ZI EINIEINI	ואום	, 210/111	Group Art Unit	1614 1624	
7	(use as many s	heets as ne	cessary)	Examiner Name	Unknown	
Chaot	1	of	1	Attorney Docket Number	A0000476-01-CFP	4

				U.S. PATENT DOC	UMENTS	
	Pages, Columns, Lines, Where Relevant					
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
						- CEN
		-				NOV
						FOUR BOOM
						CENT COUR
						TER 1600/20
						000/29
					,	
						·

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Docu Number ⁴	ment Kind Code ⁵ (<i>If known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te.
TNT	1	wo	00/09485		MCCLURE, ET AL	02/24/2000		
	1	wo	01/12611		BLAGG, ET AL	02/22/2001		
	V	wo	02/34726		NOE, ET AL	05/02/2002		
	V	wo	02/34753		BRONK, ET AL	05/02/2002		1_1
	<i>i</i> /	EP	0,935,963		MCCLURE, ET AL	08/18/1999		4—
TMT	シ	EP	1,138,680		NOE, ET AL	10/04/2001		+
								工
								+
i (! I				l		

Examiner	210	Date	7	/2 rd /0 U
Signature	Mon	Considered	6	13 /07

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.